Multiple myeloma (MM) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051124
Expand allThis document outlines details of PBS-subsidised daratumumab, elotuzumab, elranatamab, lenalidomide, pomalidomide and selinexor for patients with multiple myeloma (MM).
For details on how to process a PBS Authority, see:
- Processing Complex Authority Required Listings
- Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)
- Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
On this page:
Multiple myeloma (MM) quick reference - Initial and Balance of Supply
Multiple myeloma (MM) quick reference - Continuing and no treatment phase
Newly diagnosed triple therapy (21-day cycle for 8 cycles)
Newly diagnosed triple therapy (28-day cycle for 6 cycles)
Multiple myeloma (MM) quick reference - Initial and Balance of Supply
Table 1
Restrictions | Treatment type | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self- serve |
Initial Newly diagnosed PB291 form | Monotherapy (lenalidomide) | Written Electronic S100: lenalidomide | No | OPA | Not specified | Yes |
| Initial Newly diagnosed form | Dual therapy (lenalidomide and dexamethasone) | Written Electronic S100: lenalidomide | No | OPA | Not specified | Yes |
Initial Newly diagnosed PB293 form | Triple therapy (lenalidomide, bortezomib and dexamethasone) | Written Electronic S100: lenalidomide | No | OPA | Not specified | Yes |
| Initial Newly diagnosed (week 0-24) | Triple therapy (daratumumab, lenalidomide and dexamethasone) | Telephone Electronic S85: daratumumab S100 EFC and CT: daratumumab | No | OPA | Not specified | Yes |
Grandfather Newly diagnosed | Triple therapy (daratumumab, lenalidomide and dexamethasone) | Telephone Electronic S85: daratumumab S100 EFC and CT: daratumumab | No | OPA | Not specified | Yes |
Balance of Supply Newly diagnosed (cycles 5-6 or cycles 5-8) | Triple therapy (lenalidomide, bortezomib and dexamethasone) | Telephone Electronic S100: lenalidomide | No | OPA | Not specified | Yes |
Initial | Dual therapy (pomalidomide and dexamethasone) | Written Electronic S100: pomalidomide | No | OPA | Not specified | Yes |
Initial Progressive disease PB158 form | Monotherapy (lenalidomide) or dual therapy (lenalidomide and dexamethasone) | Written Electronic S100: lenalidomide | No | OPA | Not specified | Yes |
Initial Progressive disease | Triple therapy (pomalidomide, bortezomib and dexamethasone)) | Telephone Electronic S100: pomalidomide | No | OPA | Not specified | Yes |
Initial Relapsed and/or refractory multiple myeloma | Monotherapy (elranatamab) | Telephone Electronic S85 elranatamab S100 CT: elranatamab (general listing) | No | OPA | Not specified | Yes |
Initial Relapsed and/or refractory multiple myeloma | Dual therapy (selinexor and dexamethasone) | Telephone Electronic S100: selinexor (general listing) | No | OPA | Not specified | Yes |
Initial Relapsed and/or refractory multiple myeloma (week 1-9) | Triple therapy (daratumumab, bortezomib and dexamethasone) | Telephone Electronic S85: daratumumab S100 EFC and CT: daratumumab (general listing) | No | OPA | Not specified | Yes |
Initial Relapsed and/or refractory multiple myeloma | Triple therapy (selinexor, bortezomib and dexamethasone) | Telephone Electronic S100: selinexor (general listing) | No | OPA | Not specified | Yes |
Multiple myeloma (MM) quick reference - Continuing and no treatment phase
Table 2
Newly diagnosed triple therapy (21-day cycle for 8 cycles)
Table 3
Treatment phase | Drug combination | Treatment cycle | Quantity and repeats | Authority level | |
Initial | lenalidomide, dexamethasone and bortezomib | Cycle 1 - 4 |
| Written (PB293) Electronic | |
Continuing triple | lenalidomide, dexamethasone and bortezomib | Cycle 5 - 8 (21-day) OR Cycle 5 - 6 (28-day) |
OR
| Telephone Electronic | |
Continuing dual therapy (if continued on 21-day cycle) OR if changed to 28-day cycle If ineligible for Stem Cell Transplant (SCT) Initial newly diagnosed dual therapy If post SCT Initial newly diagnosed monotherapy | Continuing dual therapy lenalidomide and dexamethasone Ineligible for SCT lenalidomide and dexamethasone Post SCT lenalidomide | Continuing dual therapy (21-day cycle) Cycle 9 and beyond Switching to 28-day cycleN/A | Continuing dual therapy (21-day cycle)
Ineligible for SCT
Post SCT
| Continuing dual therapy (21-day cycle) Telephone Electronic Ineligible for SCT Written (PB200) Electronic Post SCT Written (PB291) Electronic |
Newly diagnosed triple therapy (28-day cycle for 6 cycles)
Table 4
Treatment phase | Drug combination | Treatment cycle | Quantity and repeats | Authority level | |
Initial | lenalidomide, dexamethasone and bortezomib | Cycle 1 - 4 |
| Written (PB293) Electronic | |
Continuing triple | lenalidomide, dexamethasone and bortezomib | Cycle 5 - 6 (28-day) OR Cycle 5 - 8 (21-day) |
OR
| Telephone Electronic | |
If continued on 28-day cycle If ineligible for SCT Initial newly diagnosed dual therapy If post SCT Initial newly diagnosed monotherapy OR Continuing dual therapy (if changed to 21-day cycle) | Ineligible for SCT lenalidomide and dexamethasone Post SCT lenalidomide Continuing dual therapy lenalidomide and dexamethasone | Continuing 28-day cycle N/A Continuing dual therapy (21-day cycle) Cycle 9 and beyond | Ineligible for SCT
Post SCT
Continuing dual therapy
| Ineligible for SCT Written (PB200) Electronic Post SCT Written (PB291) Electronic Continuing dual therapy (21-day cycle) Telephone Electronic |